In mice, testosterone stimulates erythropoiesis if they are iron-replete, but not if they are iron-deficient (30). Testosterone replacement increased soluble transferrin receptor (−0.85 −1.5, −0.2). Testosterone replacement significantly changed several parameters of iron mobilization in men with unexplained anemia (Fig. 2). Peak hemoglobin levels were reached by month 6 of treatment and persisted until month 12 (Fig. 1). Reduced hepcidin thereby increases ferroportin to mobilize iron stores and enhance iron absorption. In addition to direct simulation of the bone marrow progenitors (13, 14), testosterone has been postulated to dampen inflammation (15) and stimulate erythropoietin production by the kidneys (16). Additionally, nutrition and supplements can influence testosterone levels in weightlifters. Howthis degree of iron loading may affect one’s reproductive healthremains less clear; however, there is evidence that even this level may haveadverse effects. To discuss the physiologic and pathologic effects of iron onmen’s reproductive health. Favourable testosterone to estrogen ratio is critical for achieving optimal body composition. The role of hepcidin and iron in mediating testosterone’s stimulation of erythropoiesis, therefore, remain incompletely understood. However, testosterone was found to increase hemoglobin even in mice with genetic disruption of hepcidin (19). To investigate possible mechanisms by which testosterone stimulates erythropoiesis in hypogonadal older men with unexplained or iron-deficiency anemia. The Effect of Treatment with Testosterone or Placebo in Men in The Testosterone Trials who had Unexplained Anemia or Iron Deficiency Anemia on Erythropoietin, IL-6, CRP, and VEGF Characteristics of Participants at Baseline by Type of Anemia All hypothesis tests were conducted at a 2-sided significance level of 0.05. AbbVie (formerly Solvay and Abbott Laboratories) generously provided funding, AndroGel, and placebo gel. The Anemia Trial was additionally supported by a grant from the National Institute on Aging, National Institutes of Health (U01 AG034661) to the Partnership for Anemia Clinical and Translational Trials in the Elderly consortium. The authors also acknowledge the continued guidance and support of Drs Evan Hadley and Sergei Romashkan of the National Institute on Aging, who fostered the collaboration of the PACTTE and TTrials investigators. We express our gratitude to Dr Stanley Schrier, the chair of the Steering Committee of the Partnership for Anemia Clinical and Translational Trials in the Elderly consortium. The proportion of statistically significant results, however, greatly exceeds the type I error rate, lending credibility to our findings. Testosterone replacement did not affect the major markers of inflammation, CRP, and IL-6, in either anemic group (Table 2). P values are based on the adjusted mean differences from 0 to 12 months. Sexual dysfunction (i.e., erectile dysfunction and ejaculatory dysfunction)is a prominent complaint of men with iron overload disorders. The peroxyl radical is particularly reactive with unsaturated fattyacids—which are abundant in sperm—and result in lipid peroxidation. In mice, repeat exposure to iron oxide nanoparticles decreasessperm counts and worsens morphology . Sperm count and motilitydecrease while DNA damage and markers of oxidative stress increase . Impaired mitochondrial function would be expected tobe harmful given the extensive mitochondrial biogenesis that occurs duringspermatogenesis. While usuallyreported to adversely affect fertility, reactive oxygen species play a necessary andimportant role in sperm development and function. Interestingly, spermatozoa were the first mammalian cell identified toproduce hydrogen peroxide .
